

DAFTAR PUSTAKA

- Alkhaqani, A. (2021). Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients Attending Al-Sadder Medical Hospital in Al-Najaf City. *Turkish Journal of Physiotherapy and Rehabilitation*, 32(3), 15117–15127. <https://turkjphysiotherrehabil.org/pub/pdf/321/32-1-1859.pdf>
- Ba, S. W., Mone, P., Jankauskas, S. S., Gambardella, J., & Santulli, G. (2021). Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. 831–834. <https://doi.org/10.1111/jch.14186>
- Bella, B., El, B. P., & Oran, M. N. (2024). Performance of modification of diet in renal disease and chronic kidney disease epidemiology collaboration equations versus 99TC-DTPA-renogram in assessing kidney function. *Clinica Chimica Acta*, 558, 118639. <https://doi.org/10.1016/j.cca.2024.118639>
- Braga, C., Alves, M. G., Rodrigues, A. S., & Oliveira, P. F. (2022). Mitochondrial Pathophysiology on Chronic Kidney Disease. *International Journal of Molecular Sciences Review*.
- Chen, R. Y., & Shi, J. (2024). Evaluation of the CKD-EPI 2021 creatinine equation using laboratory data: Considerations for practice changes among clinical laboratories in British. *Clinical Biochemistry*, (November 2023), 110686. <https://doi.org/10.1016/j.clinbiochem.2023.110686>
- Enoksen, I. T., Svistounov, D., Norvik, J. V., Stefansson, V. T. N., Solbu, M. D., Eriksen, B. O., & Melsom, T. (2022). Serum matrix metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population. *Nephrology Dialysis Transplantation*, 37(9), 1657–1667. <https://doi.org/10.1093/ndt/gfab251>
- Francis, A., Harhay, M. N., Ong, A. C. M., Tummalapalli, S. L., Ortiz, A., Fogo, A. B., Fliser, D., Roy-Chaudhury, P., Fontana, M., Nangaku, M., Wanner, C., Malik, C., Hradsky, A., Adu, D., Bavanandan, S., Cusumano, A., Sola, L., Ulasi, I., & Jha, V. (2024). Chronic kidney disease and the global public health agenda: an international consensus. *Nature Reviews Nephrology*, 20(7), 473–485. <https://doi.org/10.1038/s41581-024-00820-6>
- Garland, S., Pullerits, K., Chukwu, C. A., Kalra, P. A., Chinnadurai, R., & Middleton, R. (2023). The effect of primary renal disease upon outcomes after renal transplant. *February*, 1–15. <https://doi.org/10.1111/ctr.15216>

- Hustrini, N. M., Susalit, E., Firyanto, F., Anandhara, W., & Khumaedi, I. (2024). The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta - analysis. *Journal of Epidemiology and Global Health*, 14(3), 740–764. <https://doi.org/10.1007/s44197-024-00209-5>
- Hustrini, N. M., Susalit, E., & Rotman, J. (2022). Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. *Journal of Global Health*.
- Kökény, G., Németh, Á., Kopp, J. B., Chen, W., Oler, A. J., Manzéger, A., Rosivall, L., & Mózes, M. M. (2022). Susceptibility to kidney fibrosis in mice is associated with early growth response-2 protein and tissue inhibitor of metalloproteinase-1 expression. *Kidney International*, 102(2), 337–354. <https://doi.org/10.1016/j.kint.2022.03.029>
- Mallamaci, F., & Tripepi, G. (2024). Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts. *Journal of Clinical Medicine*, 13(3), 1–12. <https://doi.org/10.3390/jcm13030678>
- Mañas, G., Tufet, J., Ruiz, J., Blanco, D. C., Ospina, F. O., Gonzalez-enguita, C., Xabier, P., Benavente, R. C., Serrano, G. B., Blanca, G., Tufet, J., Blanco, D. C., Ospina, F. O., Gonzalez-enguita, C., & Universitario, H. (2024). *World Journal of*. 13(2), 1–12. <https://doi.org/10.5527/wjn.v13.i2.93322>
- Mimura, I., Chen, Z., & Natarajan, R. (2025). Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes. *Kidney International*, 107(3), 434–456. <https://doi.org/10.1016/j.kint.2024.10.031>
- Mostafa, M. H., Tony, E. A. E., Ashmawy, A. M., Mahmoud, A. A., Othman, M. A., & Kamel, Y. M. M. (2025). Tissue inhibitor of metalloproteinase-1 and fibroscan as predictors for nonalcoholic fatty liver disease in chronic kidney disease patients attending Assiut University Hospitals. *Journal of The Egyptian Society of Nephrology and Transplantation*, 20–28. <https://doi.org/10.4103/jesnt.jesnt>
- Ntrinias, T., Papasotiriou, M., Balta, L., Kalavrizioti, D., Vamvakas, S., Papachristou, E., & Goumenos, D. S. (2019). Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. *Prilozi*, 40(3), 27–39. <https://doi.org/10.2478/prilozi-2020-0002>
- Papadopoulou-Marketou, N., Whiss, P. A., Eriksson, A. C., Hyllienmark, L., Papassotiriou, I., & Wahlberg, J. (2021). Plasma levels of tissue inhibitor of metalloproteinase-1 in patients with type 1 diabetes mellitus associate with

early diabetic neuropathy and nephropathy. *Diabetes and Vascular Disease Research*, 18(2). <https://doi.org/10.1177/14791641211002470>

Provenzano, M., Hu, L., Abenavoli, C., Cianciolo, G., Coppolino, G., De Nicola, L., La Manna, G., Comai, G., & Baraldi, O. (2024). Estimated glomerular filtration rate in observational and interventional studies in chronic kidney disease. *Journal of Nephrology*, 37(3), 573–586. <https://doi.org/10.1007/s40620-024-01887-x>

Qin, L., Wang, Y., Yang, N., Zhang, Y., Zhao, T., Wu, Y., & Jiang, J. (2021). Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic biomarker in gastrointestinal cancer: A meta-analysis. *PeerJ*, 9. <https://doi.org/10.7717/peerj.10859>

Roy, R., Macdonald, J., Dark, P., Kalra, P. A., & Green, D. (2023). The estimation of glomerular filtration in acute and critical illness: Challenges and opportunities. *Clinical Biochemistry*, 118(February), 110608. <https://doi.org/10.1016/j.clinbiochem.2023.110608>

Sandhu, G., Adattini, J., Gordon, A., Neill, N. O., Bagnis, C., Chambers, P., Martin, J. H., Flynn, A., Ibrahim, K., Jardine, M. J., Johnson, D. W., Jones, G. R. D., Karapetis, C. S., Kelly, A., Kichenadasse, G., Kliman, D. S., Liauw, W., Lucas, C., Mallett, A. J., ... Ward, R. L. (2025). Review Aligning kidney function assessment in patients with cancer to global practices in internal medicine. *eClinicalMedicine*, 103102. <https://doi.org/10.1016/j.eclinm.2025.103102>

Series, B., & Alerts, C. (2024). Chronic Kidney Disease: Etiology, Pathophysiology, and Management Strategies to Increase Quality of Life Chronic Kidney Disease - Novel Insights into Patho physiology and Treatment. <https://doi.org/10.5772/intechopen.1005083>

Speeckaert, M. M., Seegmiller, J., Glorieux, G., Lameire, N., Biesen, W. Van, Vanholder, R., & Delanghe, J. R. (2021). Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique. *Journal of Personalized Medicine*.

Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancioğlu, R., Lamb, E., Lin, P., Madero, M., McIntyre, N., Morrow, K., Roberts, G., Sabanayagam, D., Schaeffner, E., Shlipak, M., ... Levin, A. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*, 105(4), S117–S314. <https://doi.org/10.1016/j.kint.2023.10.018>

- Vaidya, S. R., & Aeddula, N. R. (2025). Chronic Kidney Disease. StatPearls NCBI Bookshelf, 1–16.
- Wang, Y., Jiao, L., Qiang, C., Chen, C., Shen, Z., Ding, F., Lv, L., Zhu, T., Lu, Y., & Cui, X. (2024). Biomedicine & Pharmacotherapy The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms. *Biomedicine & Pharmacotherapy*, 171(December 2023), 116116. <https://doi.org/10.1016/j.biopha.2023.116116>
- Warner, R. B., Najy, A. J., Jung, Y. S., Fridman, R., Kim, S., & Kim, H. R. C. (2020). Establishment of Structure-Function Relationship of Tissue Inhibitor of Metalloproteinase-1 for Its Interaction with CD63: Implication for Cancer Therapy. *Scientific Reports*, 10(1), 1–8. <https://doi.org/10.1038/s41598-020-58964-x>
- Almuntashiri, S., Dutta, S., Zhu, Y., Gamare, S., Ramírez, G., Irineo-Moreno, V., Camarena, A., Regino, N., Campero, P., Hernández-Cardenas, C. M., Rodriguez- Reyna, T. S., Zuñiga, J., Owen, C. A., Wang, X., & Zhang, D. (2024). Estrogen-dependent gene regulation: Molecular basis of *TIMP*-1 as a sex-specific biomarker for acute lung injury. *Physiological Reports*, 12(17). <https://doi.org/10.14814/phy2.70047>
- Chang, P.-Y., Chien, L.-N., Lin, Y.-F., Wu, M.-S., Chiu, W.-T., & Chiou, H.-Y. (2016). Risk factors of gender for renal progression in patients with early chronic kidney disease. *Medicine*, 95(30), e4203. <https://doi.org/10.1097/MD.00000000000004203>
- Coll, B., Rodríguez, J. A., Craver, L., Orbe, J., Martínez-Alonso, M., Ortiz, A., Díez, J., Belouqui, O., Borrás, M., Valdivielso, J. M., Fernández, E., & Páramo, J. A. (2010). Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. *Kidney International*, 78(12), 1275–1280. <https://doi.org/10.1038/ki.2010.329>
- Enoksen, I. T., Svistounov, D., Norvik, J. V., Stefansson, V. T. N., Solbu, M. D., Eriksen, B. O., & Melsom, T. (2022). Serum matrix metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population. *Nephrology Dialysis Transplantation*, 37(9), 1657–1667. <https://doi.org/10.1093/ndt/gfab251>
- Harris, R. C., & Zhang, M.-Z. (2020). The role of gender disparities in kidney injury. *Annals of Translational Medicine*, 8(7), 514–514. <https://doi.org/10.21037/atm.2020.01.23>
- Ishikawa, J., Hirose, H., & Ishikawa, S. (2019). Tissue Inhibitor of Matrix Metalloproteinase 1 Increases With Ageing and Can Be Associated With

Stroke—Nested Case-Control Study—. *Circulation Reports*, 1(11), 502–507.
<https://doi.org/10.1253/circrep.CR-19-0084>

Lieb, W., Song, R. J., Xanthakis, V., & Vasan, R. S. (2019). Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease. *Journal of the American Heart Association*, 8(7).
<https://doi.org/10.1161/JAHA.118.011426>

Mora-Gutiérrez, J. M., Rodríguez, J. A., Fernández-Seara, M. A., Orbe, J., Escalada, F. J., Soler, M. J., Slon Roblero, M. F., Riera, M., Páramo, J. A., & Garcia-Fernandez, N. (2020). MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. *Scientific Reports*, 10(1), 26. <https://doi.org/10.1038/s41598-019-56856-3>

Mostafa, M. H., Tony, E. A. E., Ashmawy, A. M., Mahmoud, A. A., Othman, M. A., & Kamel, Y. M. M. (2025). Tissue inhibitor of metalloproteinase-1 and fibroscan as predictors for nonalcoholic fatty liver disease in chronic kidney disease patients attending Assiut University Hospitals. *Journal of The Egyptian Society of Nephrology and Transplantation*, 20–28.
<https://doi.org/10.4103/jesnt.jesnt>

Musiał, K., & Zwolińska, D. (2014). Pleiotropic functions of TIMP-1 in patients with chronic kidney disease. *Cellular and Molecular Life Sciences*, 71(8), 1547–1548. <https://doi.org/10.1007/s00018-014-1592-5>

Ntrini, T., Papasotiriou, M., Balta, L., Kalavrizioti, D., Vamvakas, S., Papachristou, E., & Goumenos, D. S. (2019). Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. *PRILOZI*, 40(3), 27–39.
<https://doi.org/10.2478/prilozi-2020-0002>

Plsikova Matejova, J., Spakova, T., Harvanova, D., Lacko, M., Filip, V., Sepitka, R., Mitro, I., & Rosocha, J. (2021). A Preliminary Study of Combined Detection of COMP, TIMP-1, and MMP-3 in Synovial Fluid: Potential Indicators of Osteoarthritis Progression. *CARTILAGE*, 13(2_suppl), 1421S-1430S.
<https://doi.org/10.1177/1947603520946385>

Salman, M., Khan, A. H., Adnan, A. S., Sulaiman, S. A. S., Hussain, K., Shehzadi, N., & Jummaat, F. (2015). Attributable causes of chronic kidney disease in adults: a five-year retrospective study in a tertiary-care hospital in the northeast of the Malaysian Peninsula. *Sao Paulo Medical Journal*, 133(6), 502–509. <https://doi.org/10.1590/1516-3180.2015.005>

Tang, Y., Jiang, J., Zhao, Y., & Du, D. (2024). Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. *Clinical Kidney Journal*, 17(9). <https://doi.org/10.1093/ckj/sfae235>

Xu, T., Zhang, Y., Li, Y., Zhu, D., & Gao, P. (2014). The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients. *Renal Failure*, 36(5), 666–672. <https://doi.org/10.3109/0886022X.2014.890002>